Chemoprophylaxis of colorectal cancer in inflammatory bowel disease: Current concepts

Inflammatory Bowel Diseases

Volumn 13, Issue 10, 2007, Pages 1293-1298

  Levine, Jonathan S ^a   Burakoff, Robert ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

5 ASA; Azathioprine; Crohn's disease; Folic acid; Inflammatory bowel disease; Ulcerative colitis; Ursodeoxycholic acid

Indexed keywords

AZATHIOPRINE; BALSALAZIDE; FOLIC ACID; MERCAPTOPURINE; MESALAZINE; NONSTEROID ANTIINFLAMMATORY AGENT; SALAZOSULFAPYRIDINE; SULFAPYRIDINE; URSODEOXYCHOLIC ACID;

CHEMOPROPHYLAXIS; COLORECTAL CANCER; ENTERITIS; GASTROINTESTINAL TOXICITY; HUMAN; LOW DRUG DOSE; NONHUMAN; PATIENT COMPLIANCE; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REVIEW;

6-MERCAPTOPURINE; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; AZATHIOPRINE; CHOLAGOGUES AND CHOLERETICS; COLORECTAL NEOPLASMS; FOLIC ACID; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; MESALAMINE; TREATMENT OUTCOME; URSODEOXYCHOLIC ACID; VITAMIN B COMPLEX;

EID: 35348979243     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.20186     Document Type: Review

References (35)

1. Bernstein CN, Kliewer E, Wadja A, et al. The incidence of cancer among patients with IBD: a population-based study. Cancer. 2001;91:854-862.
2. Eaden JA, Abrams KR, Mayberry JF. The risk of CRC in ulcerative colitis: a meta-analysis. Gut. 2001;48:526-535.
3. Ekbom A, Helmick C, Zack M, et al. Ulcerative colitis and CRC. A population-based study. N Engl J Med. 1990;323:1228-1233.
4. Rutter M, Saunders B, Wilkinson K, et al. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology. 2004;126:451-459.
5. Friedman S, Rubin P, Bodian C, et al. Screening and surveillance colonoscopy in chronic Crohn's colitis. Gastroenterology. 2001;120:820-826.
6. Choi PM, Nugent FW, Schoetz DJ, et al. Colonoscopic surveillance reduces mortality from colorectal cancer in ulcerative colitis. Gastroenterology. 1993;105:418-424.
7. Karlen P, Kornfeld D, Brostrom O, et al. Is colonoscopic surveillance reducing colorectal cancer mortality in ulcerative colitis? A population based case control study. Gut. 1998;42:711-714.
8. Rutter MD, Saunders BP, Wilkinson KH, et al. Thirty-year analysis of a colonoscopic surveillance program for neoplasia in ulcerative colitis. Gastroenterology. 2006;130:1030-1038.
9. Pinczowski D, Ekbom A, Baron J. Risk factors for colorectal cancer in patients with ulcerative colitis: a case-control study. Gastroenterology. 1994;107:117-120.
10. Bernstein CN, Blanchard JF, Metge C. Does the use of 5-aminosalicylates in inflammatory bowel disease prevent the development of colorectal cancer? Am J Gastroenterol. 2003;98:2784-2788.
11. Van Staa TP, Card T, Leufkens HG. Prior aminosalicylate use and the development of colorectal cancer in inflammatory bowel disease: a large British epidemiological study. Am J Gastroenterol. 2003;A:55.
12. Velayos FS, Terdiman JP, Walsh JM. Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies. Am J Gastroenterol. 2005;100:1345-1353.
13. Rubin DT, Djordjevic A, Huo D. Use of 5-ASA is associated with decreased risk of dysplasia and colon cancer in ulcerative colitis. Gastroenterology. 2003;124:A:279.
14. Reddy SI, Friedman S, Telford J, et al. Are patients with inflammatory bowel disease receiving optimal care? Am J Gastroenterol. 2005;100:1357-1361.
15. Rubin DT, Lashner BA. Will 5-ASA keep the cancer (and dysplasia away)? Am J Gastroenterol. 2005;100:1354-1356.
16. Rubin DT, LoSavio A, Yadron N, et al. Aminosalicylate therapy in the prevention of dysplasia and colorectal cancer in ulcerative colitis. Clin Gastroenterol Hepatol. 2006;4:1346-1350.
17. Terdiman JP, Steinbuch M, Blumentals W, et al. 5-Aminosalicylic acid therapy and the risk of colorectal cancer among patients with inflammatory bowel disease. Inflamm Bowel Dis. 2007 (in press).
18. Thun MJ, Namboodiri MM, Heath CW Jr. Aspirin use and reduced risk of fatal colon cancer. N Engl J Med. 1991;325:1593-1596.
19. Chan TA. Nonsteroidal anti-inflammatory drugs, apoptosis, and colon cancer chemoprevention. Lancet Oncol. 2002;3:166-174.
20. Giovannucci E, Rimm EB, Stampfer MJ, et al. Aspririn use and the risks for colorectal cancer and adenoma in male health professionals. Ann Intern Med. 1994;121:241-246.
21. Kaiser GC, Yan F, Polk DB. Mesalamine blocks tumor necrosis factor growth inhibition and nuclear factor kappaB activation in mouse colonocytes. Gastroenterology. 1999;116:602-609.
22. Yang F, Villiers WJS, McClain CJ, et al. Mesalazine modulates nuclear factor-kB/IkB-alphas in Caco-2 cells. Gastroenterology. 1997;112(Suppl):A1125.
23. Tung BY, Edmond MJ, Haggitt C. Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Ann Intern Med. 2001;134:89-95.
24. Pardi DS, Loftus EV, Kremers WK, et al. Ursodeoxycholix acid acts as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology. 2003;124:889-893.
25. Lindor KD, The Mayo PSC/UDCA Study Group. Ursodiol for primary sclerosing cholangitis. N Engl J Med. 1997;336:691-695.
26. Martinez JF, Stratagoules ED, LaRue JM. Different bile acids exhibit distinct biological effects: the tumor promoter deoxycholic acid induces apoptosis and the chemopreventive agent ursodeoxycholic acid inhibits cell proliferation. Nutr Cancer. 1998;31:111-118.
27. Ochsenkuhn T, Bayerdorffer I, Meining A. Colonic mucosal proliferation is related to serum deoxycholic acid levels. Cancer. 1999;85:1664-1669.
28. Rodrigues CM, Kren BT, Steer CJ, et al. The site-specific delivery of ursodeoxycholic acid to the rat colon by sulfate conjugation. Gastroenterology. 1995;109:1835-1844.
29. Kim YI. Folate and carcinogenesis: evidence, mechanisms and implications. J Nutr Biochem. 1999;10:66-68.
30. Choi SW, Mason JB. Folate and carcinogenesis: an integrated scheme. J Nutr. 2000;130:129-132.
31. Fiasco G, DiMarco MC. Folate and prevention of colorectal cancer in ulcerative colitis. Cancer Prevent. 2005;14:395-398.
32. Lashner BA, Heidenreich PA, Su GL, et al. Effect of folate supplementation on the incidence of dysplasia and cancer in chronic ulcerative colitis, a case-control study. Gastroenterology. 1989;97:255-259.
33. Lashner, BA, Provencher KS, Seidner DL, et al. The effect of folic acid supplementation on the risk for cancer or dysplasia in ulcerative colitis. Gastroenterology. 1997;112:29-32.
34. Carrier J, Medline A, Sohn KJ, et al. Effects of dietary folate on ulcerative colitis-associated colorectal carcinogenesis in the interleukin 2 and beta 2 microglobulin-deficient mice. Cancer Epidemiol Biomarkers Prevent. 2003;12:1262-1267.
35. Matula S, Croog V, Itzkowitz S, et al. Chemoprevention of colorectal neoplasia in ulcerative colitis: the effect of 6-mercaptopurine. Clin Gastroenterol Hepatol. 2005;3:1015-1021.